Sebastian Bauer

Research interests

Publications

• International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020)

  Frontiers in Human Neuroscience · 2021 · 10.3389/fnhum.2020.568051

• Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

  ESMO Open · 2021 · https://doi.org/10.1016/j.esmoop.2021.100170

• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.006

• Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

  Journal of Clinical Medicine · 2021 · 10.3390/jcm10081685

• Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

  Cancer Discovery · 2021 · 10.1158/2159-8290.cd-21-0126

• Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.005

• Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.08.1995

• Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30269-2

• Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30168-6

• Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

  The Lancet · 2019 · 10.1016/s0140-6736(19)30764-0

• Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

  Annals of Oncology · 2018 · 10.1093/annonc/mdy320

• Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy310

• Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy095

• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy096

• Integrative genomic and transcriptomic analysis of leiomyosarcoma

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-017-02602-0

• Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy321

• An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx323

• Neuroinflammatory targets and treatments for epilepsy validated in experimental models

  Epilepsia · 2017 · 10.1111/epi.13783

• Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)

  Brain stimulation · 2016 · 10.1016/j.brs.2015.11.003

• Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(15)01283-0

• Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.62.9170

• Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

  Annals of Surgical Oncology · 2013 · 10.1245/s10434-013-3013-7

• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)61857-1

• One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

  JAMA · 2012 · https://doi.org/10.1001/jama.2012.347

• Cytokines and epilepsy

  Seizure · 2011 · 10.1016/j.seizure.2010.12.005

• Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70230-3

• Ontologizer 2.0—a multifunctional tool for GO term enrichment analysis and data exploration

  Bioinformatics · 2008 · 10.1093/bioinformatics/btn250

• KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

  Oncogene · 2007 · 10.1038/sj.onc.1210558

• Heat Shock Protein 90 Inhibition in Imatinib-Resistant Gastrointestinal Stromal Tumor

  Cancer Research · 2006 · 10.1158/0008-5472.can-06-0165

• Self-organized nanotubular TiO2 matrix as support for dispersed Pt/Ru nanoparticles: Enhancement of the electrocatalytic oxidation of methanol

  Electrochemistry Communications · 2005 · https://doi.org/10.1016/j.elecom.2005.09.031

• Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.

  PubMed · 2004

Current projects

No projects listed.